Active
Bill · 119th Congress · S 1095
Stop STALLING Act
Refreshed 2 h ago
Introduced 2025-03-24Topic: health careSummary
Summary by the Congressional Research ServiceStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Sponsors
- Amy Klobuchar Democrat sponsor
- 6 cosponsors
Action history
| Date | Chamber | Action | Status effect |
|---|---|---|---|
| 2025-04-10 | Senate | Placed on Senate Legislative Calendar under General Orders. Calendar No. 45. | |
| 2025-04-10 | Senate | Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report. | refer |
| 2025-04-10 | Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report. | report | |
| 2025-04-03 | Senate | Committee on the Judiciary. Ordered to be reported without amendment favorably. | refer |
| 2025-03-24 | Senate | Read twice and referred to the Committee on the Judiciary. | refer |
| 2025-03-24 | Introduced in Senate | introduce |